• Generex Biotechnology Corp., of Worcester, Mass., said in a trial of Generex Oral-lyn, a buccal spray insulin, in subjects with impaired glucose tolerance, there was a significant reduction of HbA1c compared to the control group. The company may seek to expand the use of Generex Oral-lyn beyond Type I and Type II diabetes. The results were presented at the European Association for the Study of Diabetes annual meeting in Lisbon, Portugal.

• Intercell AG, of Vienna, Austria, and Biological E. Ltd., of Hyderabad, India, completed a Phase II/III trial in 456 subjects of a vaccine for Japanese encephalitis, with positive results for safety and immunogenicity, compared to a vaccine by Korean firm Green Cross Corp. The companies will use the study to seek licensure in India. The vaccine already is approved in the U.S., Canada, Hong Kong and Australia.

• Trius Therapeutics Inc., of San Diego, completed enrollment in the first of two Phase III trials of tedizolid phosphate (formerly torezolid) in acute bacterial skin infection. The TR701-112 trial will evaluate the safety and efficacy of six days of tedizolid therapy compared to a 10-day course of Zyvox (linezolid, Pfizer Inc.) in 667 subjects. The second Phase III trial, TR701-113, will begin in late 2011.

• Vivus Inc., of Mountain View, Calif., made several presentations at the European Association for the Study of Diabetes annual meeting in Lisbon, Portugal, relating to the effect of Qnexa (phentermine/topiramate) in metabolically impaired patients. Findings showed that patients treated for more than two years with Qnexa had reductions in progression to Type II diabetes and improvements in glycemic status, and, in the SEQUEL study, among the diabetic subgroup, there was a greater percent weight loss with Qnexa compared to placebo at week 108. In the metabolic syndrome subgroup, there also was greater percent weight loss compared to placebo at week 108. The safety profile remained consistent across all three analyses and across all subgroups.